tiprankstipranks
Foghorn Therapeutics Sets 2025 Strategic Objectives
PremiumCompany AnnouncementsFoghorn Therapeutics Sets 2025 Strategic Objectives
1M ago
Foghorn Therapeutics highlights strategic objectives for 2025
Premium
The Fly
Foghorn Therapeutics highlights strategic objectives for 2025
1M ago
Foghorn Therapeutics Board Member Resignation Announced
Premium
Company Announcements
Foghorn Therapeutics Board Member Resignation Announced
2M ago
Foghorn to discontinue independent development of FHD-286 with decitabine in AML
PremiumThe FlyFoghorn to discontinue independent development of FHD-286 with decitabine in AML
2M ago
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations
Premium
Market News
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations
3M ago
Foghorn Therapeutics Reports Third Quarter Highlights
Premium
Company Announcements
Foghorn Therapeutics Reports Third Quarter Highlights
4M ago
Foghorn Therapeutics announces first patient dosed with FHD-909
PremiumThe FlyFoghorn Therapeutics announces first patient dosed with FHD-909
4M ago
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
Premium
The Fly
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
5M ago
Foghorn Therapeutics appoints Anna Rivkin as CBO
Premium
The Fly
Foghorn Therapeutics appoints Anna Rivkin as CBO
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100